POLYWASTE UK LTD
Company number 07630501 · Monitor this company
This analysis was written by an AI from the company's public filings. It may contain errors or omissions and is not financial or professional advice.
Financial Health Assessment: POLYWASTE UK LTD
Company No. 07630501 | Materials Recovery (SIC 38320) | Micro Entity | Status: In Administration
1. Financial Health Score: F — Critical Condition
This patient is in intensive care. The company has entered administration — a formal insolvency procedure under which control passes to court-appointed administrators. This is the corporate equivalent of emergency admission: it occurs when a company can no longer meet its debts as they fall due. The balance sheet confirms the severity: negative net assets of £24,011, a working capital deficit of £84,868, and liabilities that now exceed total assets. The grade reflects not just a single bad year, but an acute crisis superimposed on a chronically fragile financial constitution.
2. Key Vital Signs
| Vital Sign | FY2025 | FY2024 | Healthy Benchmark | Reading |
|---|---|---|---|---|
| Net assets | -£24,011 | +£3,078 | Positive and growing | Critical — negative equity |
| Net current assets (working capital) | -£84,868 | -£53,897 | Positive | Critical circulation failure |
| Current ratio | 0.47 | 0.63 | 1.5–2.0 | Severely hypotensive — only 47p of short-term assets per £1 of short-term debt |
| Liabilities as % of total assets | 115% | 84% | Under ~70% | Debts exceed the asset base |
| Share capital | £1 | £1 | Meaningful equity buffer | Effectively no cushion at all |
| Fixed assets | £63,555 | £82,099 | Stable/growing | Shrinking (-23%) |
| Average employees | 17 | 14 | Aligned to performance | Rising despite losses |
3. Symptoms Analysis
A chronic underlying condition. The company has never enjoyed robust health. Across a decade of filings, net assets peaked at just £40,916 (2023) and repeatedly flatlined near zero — £31 in 2017, £228 in 2019, and negative £9,305 back in 2016. This is a business that has always operated on a knife-edge of solvency, with no retained-earnings "immune system" to absorb shocks.
Acute deterioration over the last two years. The 2023 high point was rapidly reversed: implied losses of roughly £37,800 in FY2024 and a further £27,100 in FY2025 (based on the movement in shareholders' funds, with no capital injections evident). Two years of bleeding erased everything the company had accumulated.
A shrinking body with a growing burden. Total assets have contracted by around 40% from their 2023 peak (£228,729 → £138,396), while total liabilities have climbed ~17.5% over the same period (£135,891 → £159,709). Assets down, debts up — the classic distress pattern.
Obligations bunching into the near term. Long-term creditors fell from £25,124 to £2,698, while short-term creditors rose to £159,709. Pressure is concentrating in the "due within one year" category — precisely where a company with a 0.47 current ratio can least afford it.
Cost base expanding against the tide. Average headcount grew from 14 to 17 even as losses mounted — a symptom of costs rising while financial strength drained away.
Minimal capitalization. With share capital of £1, there is no equity buffer whatsoever; every pound of loss falls directly onto creditors.
4. Diagnosis
Acute insolvency on a chronically undercapitalized constitution.
- Balance-sheet insolvency: liabilities exceed assets by £24,011 — negative equity confirmed in the filed accounts.
- Probable cash-flow insolvency: current assets cover less than half of debts due within a year; the administration appointment corroborates that the company could not pay its way.
- Root cause: a business model that produced wafer-thin margins for years, never building reserves, leaving the company defenceless when trading conditions or costs turned against it.
Diagnostic caveat: the company files micro-entity, filleted accounts with audit exemption and no public profit and loss account. This assessment is therefore based on balance-sheet evidence only — the equivalent of diagnosing without full blood work.
5. Prognosis: Guarded
Administration provides a controlled clinical environment in which rescue is possible, but not guaranteed. Realistic outcomes include a sale of the business as a going concern, realization of assets, a company voluntary arrangement, or — failing those — progression toward liquidation. There are signs of residual underlying value: £63,555 of fixed assets (consistent with plant and equipment for materials recovery) and an operating workforce. However, the £84,868 working-capital hole and negative equity mean recovery prospects for unsecured creditors are uncertain, and any standalone survival would require substantial new capital that the current £1 equity base plainly cannot supply.
6. Recommendations
For creditors and other stakeholders: - Lodge a proof of debt with the administrators promptly and monitor the administrators' proposals (normally circulated within about eight weeks of appointment). - Engage with any creditors' committee formed, and treat recovery timelines as uncertain.
For any rescue or going-concern sale scenario: - Recapitalize genuinely. The £1 share capital must be replaced with real equity investment; without it, any rescued entity is born with the same congenital weakness. - Restructure the cost base. Align headcount and overheads with realistic revenue — staffing grew while losses deepened. - Review the asset base. Assess whether the £63,555 of fixed assets is fully utilized or whether disposals could reduce creditor pressure. - Rebuild working capital discipline. Tight debtor collection, creditor term renegotiation, and weekly cash-flow forecasting are essential to restore circulation. - Upgrade financial visibility. Move beyond minimal micro-entity reporting to monthly management accounts, so deterioration is detected at symptom stage rather than emergency stage.